Leadiant’s fine for excessive pricing for CTX drug upheld by Dutch court
MLex Summary: Pharmaceutical company Leadiant has seen the Rotterdam District Court uphold a penalty that the Dutch competition authority imposed on it for charging excessive prices for chenodeoxycholic acid, or CDCA....To view the full article, register now.
Already a subscriber? Click here to view full article